Research Analysts Offer Predictions for Nuwellis Q2 Earnings

Nuwellis, Inc. (NASDAQ:NUWE) – Research analysts at Roth Capital decreased their Q2 2025 EPS estimates for shares of Nuwellis in a research note issued on Tuesday, May 13th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings per share of ($0.45) for the quarter, down from their prior estimate of ($0.36). Roth Capital currently has a “Buy” rating on the stock. The consensus estimate for Nuwellis’ current full-year earnings is ($8.17) per share. Roth Capital also issued estimates for Nuwellis’ Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at ($1.93) EPS, FY2026 earnings at ($0.92) EPS, FY2027 earnings at ($0.04) EPS and FY2029 earnings at $1.42 EPS.

Nuwellis (NASDAQ:NUWE) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.24). Nuwellis had a negative return on equity of 28,159.25% and a negative net margin of 169.54%. The business had revenue of $1.90 million during the quarter, compared to the consensus estimate of $2.50 million.

Nuwellis Stock Performance

Nuwellis stock opened at $0.94 on Friday. The firm’s 50-day moving average is $0.97 and its 200-day moving average is $1.19. Nuwellis has a 1 year low of $0.75 and a 1 year high of $11.66. The company has a market cap of $4.11 million, a P/E ratio of -0.01 and a beta of 0.51.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Nuwellis stock. Geode Capital Management LLC purchased a new position in Nuwellis, Inc. (NASDAQ:NUWE) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 30,806 shares of the company’s stock, valued at approximately $34,000. Geode Capital Management LLC owned about 0.70% of Nuwellis as of its most recent filing with the Securities and Exchange Commission. 3.13% of the stock is currently owned by hedge funds and other institutional investors.

About Nuwellis

Nuwellis, Inc, a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter.